Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Keith Douglas Lillemoe, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Keith Lillemoe and Motaz Qadan.
Keith Lillemoe
Connection Strength
6.093
Motaz Qadan
  1. A Multidisciplinary Team Approach for Triage of Elective Cancer Surgery at the Massachusetts General Hospital During the Novel Coronavirus COVID-19 Outbreak. Ann Surg. 2020 07; 272(1):e20-e21.
    View in: PubMed
    Score: 0.906
  2. Analysis of in court malpractice litigation following pancreatic surgery. Pancreatology. 2021 Jun; 21(4):819-823.
    View in: PubMed
    Score: 0.237
  3. Size of the Largest Colorectal Liver Metastasis Is an Independent Prognostic Factor in the Neoadjuvant Setting. J Surg Res. 2021 03; 259:253-260.
    View in: PubMed
    Score: 0.232
  4. Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Pancreas. 2020 08; 49(7):897-903.
    View in: PubMed
    Score: 0.228
  5. Diagnosis of Depression is Associated with Readmission Following Elective Pancreatectomy. Ann Surg Oncol. 2020 Oct; 27(11):4544-4550.
    View in: PubMed
    Score: 0.224
  6. Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. Am J Surg. 2020 07; 220(1):29-34.
    View in: PubMed
    Score: 0.223
  7. Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. Pancreatology. 2020 Jun; 20(4):691-697.
    View in: PubMed
    Score: 0.222
  8. Does preoperative pharmacologic prophylaxis reduce the rate of venous thromboembolism in pancreatectomy patients? HPB (Oxford). 2020 07; 22(7):1020-1024.
    View in: PubMed
    Score: 0.217
  9. Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2019 Nov; 26(12):4091-4099.
    View in: PubMed
    Score: 0.212
  10. Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection. Am J Surg. 2019 11; 218(5):959-966.
    View in: PubMed
    Score: 0.206
  11. Intraoperative Fluid Administration and Surgical Outcomes Following Pancreaticoduodenectomy: External Validation at a Tertiary Referral Center. World J Surg. 2019 Mar; 43(3):929-936.
    View in: PubMed
    Score: 0.206
  12. Contemporary Opportunity for Prehabilitation as Part of an Enhanced Recovery after Surgery Pathway in Colorectal Surgery. Clin Colon Rectal Surg. 2019 Mar; 32(2):95-101.
    View in: PubMed
    Score: 0.206
  13. Surgical resection versus ablation for early-stage hepatocellular carcinoma: A retrospective cohort analysis. Am J Surg. 2019 07; 218(1):157-163.
    View in: PubMed
    Score: 0.204
  14. Lower phosphate levels following pancreatectomy is associated with postoperative pancreatic fistula formation. HPB (Oxford). 2019 07; 21(7):834-840.
    View in: PubMed
    Score: 0.203
  15. The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis. Ann Surg. 2021 11 01; 274(5):721-728.
    View in: PubMed
    Score: 0.062
  16. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy. Eur Radiol. 2021 Oct 19.
    View in: PubMed
    Score: 0.062
  17. "Evolving Trends in Pancreatic Cystic Tumors: A 3-Decade Single-Center Experience with 1290 Resections". Ann Surg. 2021 Aug 04.
    View in: PubMed
    Score: 0.061
  18. Simulated Volume-Based Regionalization of Complex Procedures: Impact on Spatial Access to Care. Ann Surg. 2021 08 01; 274(2):312-318.
    View in: PubMed
    Score: 0.061
  19. Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma. Ann Surg. 2021 08 01; 274(2):e134-e142.
    View in: PubMed
    Score: 0.061
  20. Management of Pneumoperitoneum: Role and Limits of Nonoperative Treatment. Ann Surg. 2021 07 01; 274(1):146-154.
    View in: PubMed
    Score: 0.061
  21. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Br J Surg. 2021 06 22; 108(6):709-716.
    View in: PubMed
    Score: 0.061
  22. Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. Pancreatology. 2021 May 15.
    View in: PubMed
    Score: 0.060
  23. Assessment of the Long-Term Impact of Pancreatoduodenectomy on Health-Related Quality of Life Using the EORTC QLQ-PAN26 Module. Ann Surg Oncol. 2021 Aug; 28(8):4216-4224.
    View in: PubMed
    Score: 0.060
  24. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. J Natl Cancer Inst. 2021 02 01; 113(2):182-191.
    View in: PubMed
    Score: 0.059
  25. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. J Gastrointest Surg. 2021 Jan 26.
    View in: PubMed
    Score: 0.059
  26. Patient and Caregiver Considerations and Priorities When Selecting Hospitals for Complex Cancer Care. Ann Surg Oncol. 2021 Aug; 28(8):4183-4192.
    View in: PubMed
    Score: 0.059
  27. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation. Ann Surg Oncol. 2021 Aug; 28(8):4592-4601.
    View in: PubMed
    Score: 0.059
  28. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg. 2020 Nov 09.
    View in: PubMed
    Score: 0.058
  29. Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection. Ann Surg. 2020 11; 272(5):731-737.
    View in: PubMed
    Score: 0.058
  30. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Ann Surg. 2020 Oct 19.
    View in: PubMed
    Score: 0.058
  31. Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma. Ann Surg. 2020 Oct 19.
    View in: PubMed
    Score: 0.058
  32. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Br J Surg. 2020 Sep 30.
    View in: PubMed
    Score: 0.058
  33. Preoperative cholangitis is an independent risk factor for mortality in patients after pancreatoduodenectomy for pancreatic cancer. Am J Surg. 2021 01; 221(1):134-140.
    View in: PubMed
    Score: 0.057
  34. Risk of malignancy in small pancreatic cysts decreases over time. Pancreatology. 2020 Sep; 20(6):1213-1217.
    View in: PubMed
    Score: 0.057
  35. Implications of COVID-19 on the General Surgery Match. Ann Surg. 2020 08; 272(2):e155-e156.
    View in: PubMed
    Score: 0.057
  36. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Ann Surg. 2020 08; 272(2):357-365.
    View in: PubMed
    Score: 0.057
  37. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: The PANAMA-score. Ann Surg. 2020 Jul 07.
    View in: PubMed
    Score: 0.057
  38. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. Histopathology. 2020 Jul; 77(1):144-155.
    View in: PubMed
    Score: 0.057
  39. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. Histopathology. 2020 Jul; 77(1):35-45.
    View in: PubMed
    Score: 0.056
  40. Implications of COVID-19 on the General Surgery Match. Ann Surg. 2020 May 20.
    View in: PubMed
    Score: 0.056
  41. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2020 Oct; 27(10):3898-3912.
    View in: PubMed
    Score: 0.056
  42. An elevated CA 19-9 is associated with invasive cancer and worse survival in IPMN. Pancreatology. 2020 Jun; 20(4):729-735.
    View in: PubMed
    Score: 0.056
  43. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. Pancreatology. 2020 Jun; 20(4):722-728.
    View in: PubMed
    Score: 0.055
  44. Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?: Results from a Multi-institutional Study. Ann Surg. 2019 Dec 05.
    View in: PubMed
    Score: 0.054
  45. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. Ann Surg Oncol. 2020 May; 27(5):1400-1406.
    View in: PubMed
    Score: 0.054
  46. Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer. Ann Surg Oncol. 2020 May; 27(5):1606-1612.
    View in: PubMed
    Score: 0.054
  47. Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic cancer. Pancreatology. 2020 Jan; 20(1):125-131.
    View in: PubMed
    Score: 0.054
  48. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy. JAMA Surg. 2019 10 01; 154(10):943-951.
    View in: PubMed
    Score: 0.054
  49. Deficits in the Palliative Care Process Measures in Patients with Advanced Pancreatic Cancer Undergoing Operative and Invasive Nonoperative Palliative Procedures. Ann Surg Oncol. 2019 Dec; 26(13):4204-4212.
    View in: PubMed
    Score: 0.053
  50. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jul 01; 5(7):1020-1027.
    View in: PubMed
    Score: 0.053
  51. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg. 2019 04; 269(4):733-740.
    View in: PubMed
    Score: 0.052
  52. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Ann Surg. 2019 Jan 18.
    View in: PubMed
    Score: 0.051
  53. Intraoperative Dexamethasone Decreases Infectious Complications After Pancreaticoduodenectomy and is Associated with Long-Term Survival in Pancreatic Cancer. Ann Surg Oncol. 2018 Dec; 25(13):4020-4026.
    View in: PubMed
    Score: 0.050
  54. Major Complications Independently Increase Long-Term Mortality After Pancreatoduodenectomy for Cancer. J Gastrointest Surg. 2019 10; 23(10):1984-1990.
    View in: PubMed
    Score: 0.050
  55. Staging Laparoscopy Not Only Saves Patients an Incision, But May Also Help Them Live Longer. Ann Surg Oncol. 2018 Apr; 25(4):1009-1016.
    View in: PubMed
    Score: 0.048
  56. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. J Gastrointest Surg. 2017 Nov; 21(11):1831-1840.
    View in: PubMed
    Score: 0.047
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.